APO Research
Talk to an analyst

APO RESEARCH · REPORT

AI Pharma

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global AI Pharma Market Analysis and Forecast 2026-2032

2 January 2026218 pages

Choose your research edition.

Industry ResearchAI Pharma Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal AI Pharma Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal AI Pharma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AI Pharma Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal AI Pharma Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global AI Pharma market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for AI Pharma is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for AI Pharma is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for AI Pharma is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for AI Pharma is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of AI Pharma include Recursion, Insilico Medicine, Exscientia, BenevolentAI, Atomwise, Roivant Sciences, Schrödinger, Lantern Pharma and XtalPi, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for AI Pharma, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of AI Pharma, also provides the revenue of main regions and countries. Of the upcoming market potential for AI Pharma, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the AI Pharma revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global AI Pharma market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for AI Pharma revenue, projected growth trends, production technology, application and end-user industry.

AI Pharma Segment by Company

Recursion

Insilico Medicine

Exscientia

BenevolentAI

Atomwise

Roivant Sciences

Schrödinger

Lantern Pharma

XtalPi

Landos Biopharma

Relay Therapeutics

Accutar Biotech

Deep Genomics

Oncocross

AI Therapeutics

BioMap

METiS Pharmaceuticals

NeoX Biotech

StoneWise

Deep Intelligent Pharma

Gigaceuticals

Chemical.AI

Artivila

Galixir

Xbiome

AI Pharma Segment by Type

Self-developed Oipeline

Contract Research Organization (CRO)

Other

AI Pharma Segment by Application

Preclinical Stage (Optimization of Lead Compounds, etc.)

Clinical Trial Phase (Predicting Treatment Outcome, etc.)

AI Pharma Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Pharma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AI Pharma and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Pharma.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of AI Pharma in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of AI Pharma company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, AI Pharma revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global AI Pharma Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Self-developed Oipeline Major Player Table 3. Contract Research Organization (CRO) Major Player Table 4. Other Major Player Table 5. Global AI Pharma Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Preclinical Stage (Optimization of Lead Compounds, etc.) Major Player Table 7. Clinical Trial Phase (Predicting Treatment Outcome, etc.) Major Player Table 8. AI Pharma Industry Trends Table 9. AI Pharma Industry Drivers Table 10. AI Pharma Industry Opportunities and Challenges Table 11. AI Pharma Industry Restraints Table 12. Global AI Pharma Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global AI Pharma Market Size by Region (2021-2026) & (US$ Million) Table 14. Global AI Pharma Market Share by Region (2021-2026) Table 15. Global AI Pharma Market Size by Region (2027-2032) & (US$ Million) Table 16. Global AI Pharma Market Share by Region (2027-2032) Table 17. Global AI Pharma Revenue by Players (US$ Million) & (2021-2026) Table 18. Global AI Pharma Revenue Market Share by Players (2021-2026) Table 19. Global AI Pharma Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global AI Pharma Key Players Headquarters & Area Served Table 21. Global AI Pharma Players, Product Type & Application Table 22. Global AI Pharma Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global AI Pharma by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global AI Pharma Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global AI Pharma Revenue by Type (2021-2026) & (US$ Million) Table 27. Global AI Pharma Revenue by Type (2027-2032) & (US$ Million) Table 28. Global AI Pharma Revenue Market Share by Type (2021-2026) Table 29. Global AI Pharma Revenue Market Share by Type (2027-2032) Table 30. Global AI Pharma Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global AI Pharma Revenue by Application (2021-2026) & (US$ Million) Table 32. Global AI Pharma Revenue by Application (2027-2032) & (US$ Million) Table 33. Global AI Pharma Revenue Market Share by Application (2021-2026) Table 34. Global AI Pharma Revenue Market Share by Application (2027-2032) Table 35. Recursion Company Information Table 36. Recursion Business Overview Table 37. Recursion AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Recursion AI Pharma Product Portfolio Table 39. Recursion Recent Development Table 40. Insilico Medicine Company Information Table 41. Insilico Medicine Business Overview Table 42. Insilico Medicine AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Insilico Medicine AI Pharma Product Portfolio Table 44. Insilico Medicine Recent Development Table 45. Exscientia Company Information Table 46. Exscientia Business Overview Table 47. Exscientia AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Exscientia AI Pharma Product Portfolio Table 49. Exscientia Recent Development Table 50. BenevolentAI Company Information Table 51. BenevolentAI Business Overview Table 52. BenevolentAI AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. BenevolentAI AI Pharma Product Portfolio Table 54. BenevolentAI Recent Development Table 55. Atomwise Company Information Table 56. Atomwise Business Overview Table 57. Atomwise AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Atomwise AI Pharma Product Portfolio Table 59. Atomwise Recent Development Table 60. Roivant Sciences Company Information Table 61. Roivant Sciences Business Overview Table 62. Roivant Sciences AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Roivant Sciences AI Pharma Product Portfolio Table 64. Roivant Sciences Recent Development Table 65. Schrödinger Company Information Table 66. Schrödinger Business Overview Table 67. Schrödinger AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Schrödinger AI Pharma Product Portfolio Table 69. Schrödinger Recent Development Table 70. Lantern Pharma Company Information Table 71. Lantern Pharma Business Overview Table 72. Lantern Pharma AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Lantern Pharma AI Pharma Product Portfolio Table 74. Lantern Pharma Recent Development Table 75. XtalPi Company Information Table 76. XtalPi Business Overview Table 77. XtalPi AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. XtalPi AI Pharma Product Portfolio Table 79. XtalPi Recent Development Table 80. Landos Biopharma Company Information Table 81. Landos Biopharma Business Overview Table 82. Landos Biopharma AI Pharma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Landos Biopharma AI Pharma Product Portfolio Table 84. Landos Biopharma Recent Development Table 85. Relay Therapeutics Company Information Table 86. Relay Therapeutics Business Overview Table 87. Relay Therapeutics AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Relay Therapeutics AI Pharma Product Portfolio Table 89. Relay Therapeutics Recent Development Table 90. Accutar Biotech Company Information Table 91. Accutar Biotech Business Overview Table 92. Accutar Biotech AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Accutar Biotech AI Pharma Product Portfolio Table 94. Accutar Biotech Recent Development Table 95. Deep Genomics Company Information Table 96. Deep Genomics Business Overview Table 97. Deep Genomics AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Deep Genomics AI Pharma Product Portfolio Table 99. Deep Genomics Recent Development Table 100. Oncocross Company Information Table 101. Oncocross Business Overview Table 102. Oncocross AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Oncocross AI Pharma Product Portfolio Table 104. Oncocross Recent Development Table 105. AI Therapeutics Company Information Table 106. AI Therapeutics Business Overview Table 107. AI Therapeutics AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. AI Therapeutics AI Pharma Product Portfolio Table 109. AI Therapeutics Recent Development Table 110. BioMap Company Information Table 111. BioMap Business Overview Table 112. BioMap AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. BioMap AI Pharma Product Portfolio Table 114. BioMap Recent Development Table 115. METiS Pharmaceuticals Company Information Table 116. METiS Pharmaceuticals Business Overview Table 117. METiS Pharmaceuticals AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. METiS Pharmaceuticals AI Pharma Product Portfolio Table 119. METiS Pharmaceuticals Recent Development Table 120. NeoX Biotech Company Information Table 121. NeoX Biotech Business Overview Table 122. NeoX Biotech AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. NeoX Biotech AI Pharma Product Portfolio Table 124. NeoX Biotech Recent Development Table 125. StoneWise Company Information Table 126. StoneWise Business Overview Table 127. StoneWise AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. StoneWise AI Pharma Product Portfolio Table 129. StoneWise Recent Development Table 130. Deep Intelligent Pharma Company Information Table 131. Deep Intelligent Pharma Business Overview Table 132. Deep Intelligent Pharma AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Deep Intelligent Pharma AI Pharma Product Portfolio Table 134. Deep Intelligent Pharma Recent Development Table 135. Gigaceuticals Company Information Table 136. Gigaceuticals Business Overview Table 137. Gigaceuticals AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Gigaceuticals AI Pharma Product Portfolio Table 139. Gigaceuticals Recent Development Table 140. Chemical.AI Company Information Table 141. Chemical.AI Business Overview Table 142. Chemical.AI AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Chemical.AI AI Pharma Product Portfolio Table 144. Chemical.AI Recent Development Table 145. Artivila Company Information Table 146. Artivila Business Overview Table 147. Artivila AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Artivila AI Pharma Product Portfolio Table 149. Artivila Recent Development Table 150. Galixir Company Information Table 151. Galixir Business Overview Table 152. Galixir AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Galixir AI Pharma Product Portfolio Table 154. Galixir Recent Development Table 155. Xbiome Company Information Table 156. Xbiome Business Overview Table 157. Xbiome AI Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Xbiome AI Pharma Product Portfolio Table 159. Xbiome Recent Development Table 160. North America AI Pharma Revenue by Type (2021-2026) & (US$ Million) Table 161. North America AI Pharma Revenue by Type (2027-2032) & (US$ Million) Table 162. North America AI Pharma Revenue by Application (2021-2026) & (US$ Million) Table 163. North America AI Pharma Revenue by Application (2027-2032) & (US$ Million) Table 164. North America AI Pharma Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. North America AI Pharma Revenue by Country (2021-2026) & (US$ Million) Table 166. North America AI Pharma Revenue by Country (US$ Million) & (2027-2032) Table 167. Europe AI Pharma Revenue by Type (2021-2026) & (US$ Million) Table 168. Europe AI Pharma Revenue by Type (2027-2032) & (US$ Million) Table 169. Europe AI Pharma Revenue by Application (2021-2026) & (US$ Million) Table 170. Europe AI Pharma Revenue by Application (2027-2032) & (US$ Million) Table 171. Europe AI Pharma Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 172. Europe AI Pharma Revenue by Country (2021-2026) & (US$ Million) Table 173. Europe AI Pharma Revenue by Country (US$ Million) & (2027-2032) Table 174. China AI Pharma Revenue by Type (2021-2026) & (US$ Million) Table 175. China AI Pharma Revenue by Type (2027-2032) & (US$ Million) Table 176. China AI Pharma Revenue by Application (2021-2026) & (US$ Million) Table 177. China AI Pharma Revenue by Application (2027-2032) & (US$ Million) Table 178. Asia AI Pharma Revenue by Type (2021-2026) & (US$ Million) Table 179. Asia AI Pharma Revenue by Type (2027-2032) & (US$ Million) Table 180. Asia AI Pharma Revenue by Application (2021-2026) & (US$ Million) Table 181. Asia AI Pharma Revenue by Application (2027-2032) & (US$ Million) Table 182. Asia AI Pharma Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 183. Asia AI Pharma Revenue by Region (US$ Million) & (2021-2026) Table 184. Asia AI Pharma Revenue by Region (US$ Million) & (2027-2032) Table 185. SAMEA AI Pharma Revenue by Type (2021-2026) & (US$ Million) Table 186. SAMEA AI Pharma Revenue by Type (2027-2032) & (US$ Million) Table 187. SAMEA AI Pharma Revenue by Application (2021-2026) & (US$ Million) Table 188. SAMEA AI Pharma Revenue by Application (2027-2032) & (US$ Million) Table 189. SAMEA AI Pharma Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 190. SAMEA AI Pharma Revenue by Country (2021-2026) & (US$ Million) Table 191. SAMEA AI Pharma Revenue by Country (US$ Million) & (2027-2032) Table 192. Research Programs/Design for This Report Table 193. Authors List of This Report Table 194. Secondary Sources Table 195. Primary Sources List of Figures Figure 1. AI Pharma Image Figure 2. Global AI Pharma Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AI Pharma Market Size Share 2021 VS 2025 VS 2032 Figure 4. Self-developed Oipeline Image Figure 5. Contract Research Organization (CRO) Image Figure 6. Other Image Figure 7. Global AI Pharma Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global AI Pharma Market Size Share 2021 VS 2025 VS 2032 Figure 9. Preclinical Stage (Optimization of Lead Compounds, etc.) Image Figure 10. Clinical Trial Phase (Predicting Treatment Outcome, etc.) Image Figure 11. Global AI Pharma Market Size (US$ Million) & (2021-2032) Figure 12. Global AI Pharma Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global AI Pharma Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global AI Pharma Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global AI Pharma Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global AI Pharma Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global AI Pharma Revenue Market Share by Type (2021-2032) Figure 19. Global AI Pharma Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global AI Pharma Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global AI Pharma Revenue Market Share by Application (2021-2032) Figure 22. North America AI Pharma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America AI Pharma Revenue Share by Type (2021-2032) Figure 24. North America AI Pharma Revenue Share by Application (2021-2032) Figure 25. North America AI Pharma Revenue Share by Country (2021-2032) Figure 26. United States AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe AI Pharma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe AI Pharma Revenue Share by Type (2021-2032) Figure 31. Europe AI Pharma Revenue Share by Application (2021-2032) Figure 32. Europe AI Pharma Revenue Share by Country (2021-2032) Figure 33. Germany AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China AI Pharma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China AI Pharma Revenue Share by Type (2021-2032) Figure 43. China AI Pharma Revenue Share by Application (2021-2032) Figure 44. Asia AI Pharma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia AI Pharma Revenue Share by Type (2021-2032) Figure 46. Asia AI Pharma Revenue Share by Application (2021-2032) Figure 47. Asia AI Pharma Revenue Share by Region (2021-2032) Figure 48. Japan AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA AI Pharma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA AI Pharma Revenue Share by Type (2021-2032) Figure 56. SAMEA AI Pharma Revenue Share by Application (2021-2032) Figure 57. SAMEA AI Pharma Revenue Share by Country (2021-2032) Figure 58. Brazil AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt AI Pharma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Self-developed Oipeline
  • Contract Research Organization (CRO)
  • Other
Applications
  • Preclinical Stage (Optimization of Lead Compounds, etc.)
  • Clinical Trial Phase (Predicting Treatment Outcome, etc.)
Companies covered
  • Recursion
  • Insilico Medicine
  • Exscientia
  • BenevolentAI
  • Atomwise
  • Roivant Sciences
  • Schrödinger
  • Lantern Pharma
  • XtalPi
  • Landos Biopharma
  • Relay Therapeutics
  • Accutar Biotech
  • Deep Genomics
  • Oncocross
  • AI Therapeutics
  • BioMap
  • METiS Pharmaceuticals
  • NeoX Biotech
  • StoneWise
  • Deep Intelligent Pharma
  • Gigaceuticals
  • Chemical.AI
  • Artivila
  • Galixir
  • Xbiome

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 AI Pharma Market by Type
  3. 1.2.1 Global AI Pharma Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Self-developed Oipeline
  5. 1.2.3 Contract Research Organization (CRO)
  6. 1.2.4 Other
  7. 1.3 AI Pharma Market by Application
  8. 1.3.1 Global AI Pharma Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Preclinical Stage (Optimization of Lead Compounds, etc.)
  10. 1.3.3 Clinical Trial Phase (Predicting Treatment Outcome, etc.)
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 AI Pharma Market Dynamics
  1. 2.1 AI Pharma Industry Trends
  2. 2.2 AI Pharma Industry Drivers
  3. 2.3 AI Pharma Industry Opportunities and Challenges
  4. 2.4 AI Pharma Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global AI Pharma Market Perspective (2021-2032)
  2. 3.2 Global AI Pharma Growth Trends by Region
  3. 3.2.1 Global AI Pharma Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global AI Pharma Market Size by Region (2021-2026)
  5. 3.2.3 Global AI Pharma Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global AI Pharma Revenue by Players
  2. 4.1.1 Global AI Pharma Revenue by Players (2021-2026)
  3. 4.1.2 Global AI Pharma Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global AI Pharma Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global AI Pharma Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global AI Pharma Key Players Headquarters & Area Served
  7. 4.4 Global AI Pharma Players, Product Type & Application
  8. 4.5 Global AI Pharma Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global AI Pharma Market CR5 and HHI
  11. 4.6.3 2025 AI Pharma Tier 1, Tier 2, and Tier 3
5 AI Pharma Market Size by Type
  1. 5.1 Global AI Pharma Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global AI Pharma Revenue by Type (2021-2032)
  3. 5.3 Global AI Pharma Revenue Market Share by Type (2021-2032)
6 AI Pharma Market Size by Application
  1. 6.1 Global AI Pharma Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global AI Pharma Revenue by Application (2021-2032)
  3. 6.3 Global AI Pharma Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Recursion
  2. 7.1.1 Recursion Company Information
  3. 7.1.2 Recursion Business Overview
  4. 7.1.3 Recursion AI Pharma Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Recursion AI Pharma Product Portfolio
  6. 7.1.5 Recursion Recent Developments
  7. 7.2 Insilico Medicine
  8. 7.2.1 Insilico Medicine Company Information
  9. 7.2.2 Insilico Medicine Business Overview
  10. 7.2.3 Insilico Medicine AI Pharma Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Insilico Medicine AI Pharma Product Portfolio
  12. 7.2.5 Insilico Medicine Recent Developments
  13. 7.3 Exscientia
  14. 7.3.1 Exscientia Company Information
  15. 7.3.2 Exscientia Business Overview
  16. 7.3.3 Exscientia AI Pharma Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Exscientia AI Pharma Product Portfolio
  18. 7.3.5 Exscientia Recent Developments
  19. 7.4 BenevolentAI
  20. 7.4.1 BenevolentAI Company Information
  21. 7.4.2 BenevolentAI Business Overview
  22. 7.4.3 BenevolentAI AI Pharma Revenue and Gross Margin (2021-2026)
  23. 7.4.4 BenevolentAI AI Pharma Product Portfolio
  24. 7.4.5 BenevolentAI Recent Developments
  25. 7.5 Atomwise
  26. 7.5.1 Atomwise Company Information
  27. 7.5.2 Atomwise Business Overview
  28. 7.5.3 Atomwise AI Pharma Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Atomwise AI Pharma Product Portfolio
  30. 7.5.5 Atomwise Recent Developments
  31. 7.6 Roivant Sciences
  32. 7.6.1 Roivant Sciences Company Information
  33. 7.6.2 Roivant Sciences Business Overview
  34. 7.6.3 Roivant Sciences AI Pharma Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Roivant Sciences AI Pharma Product Portfolio
  36. 7.6.5 Roivant Sciences Recent Developments
  37. 7.7 Schrödinger
  38. 7.7.1 Schrödinger Company Information
  39. 7.7.2 Schrödinger Business Overview
  40. 7.7.3 Schrödinger AI Pharma Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Schrödinger AI Pharma Product Portfolio
  42. 7.7.5 Schrödinger Recent Developments
  43. 7.8 Lantern Pharma
  44. 7.8.1 Lantern Pharma Company Information
  45. 7.8.2 Lantern Pharma Business Overview
  46. 7.8.3 Lantern Pharma AI Pharma Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Lantern Pharma AI Pharma Product Portfolio
  48. 7.8.5 Lantern Pharma Recent Developments
  49. 7.9 XtalPi
  50. 7.9.1 XtalPi Company Information
  51. 7.9.2 XtalPi Business Overview
  52. 7.9.3 XtalPi AI Pharma Revenue and Gross Margin (2021-2026)
  53. 7.9.4 XtalPi AI Pharma Product Portfolio
  54. 7.9.5 XtalPi Recent Developments
  55. 7.10 Landos Biopharma
  56. 7.10.1 Landos Biopharma Company Information
  57. 7.10.2 Landos Biopharma Business Overview
  58. 7.10.3 Landos Biopharma AI Pharma Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Landos Biopharma AI Pharma Product Portfolio
  60. 7.10.5 Landos Biopharma Recent Developments
  61. 7.11 Relay Therapeutics
  62. 7.11.1 Relay Therapeutics Company Information
  63. 7.11.2 Relay Therapeutics Business Overview
  64. 7.11.3 Relay Therapeutics AI Pharma Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Relay Therapeutics AI Pharma Product Portfolio
  66. 7.11.5 Relay Therapeutics Recent Developments
  67. 7.12 Accutar Biotech
  68. 7.12.1 Accutar Biotech Company Information
  69. 7.12.2 Accutar Biotech Business Overview
  70. 7.12.3 Accutar Biotech AI Pharma Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Accutar Biotech AI Pharma Product Portfolio
  72. 7.12.5 Accutar Biotech Recent Developments
  73. 7.13 Deep Genomics
  74. 7.13.1 Deep Genomics Company Information
  75. 7.13.2 Deep Genomics Business Overview
  76. 7.13.3 Deep Genomics AI Pharma Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Deep Genomics AI Pharma Product Portfolio
  78. 7.13.5 Deep Genomics Recent Developments
  79. 7.14 Oncocross
  80. 7.14.1 Oncocross Company Information
  81. 7.14.2 Oncocross Business Overview
  82. 7.14.3 Oncocross AI Pharma Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Oncocross AI Pharma Product Portfolio
  84. 7.14.5 Oncocross Recent Developments
  85. 7.15 AI Therapeutics
  86. 7.15.1 AI Therapeutics Company Information
  87. 7.15.2 AI Therapeutics Business Overview
  88. 7.15.3 AI Therapeutics AI Pharma Revenue and Gross Margin (2021-2026)
  89. 7.15.4 AI Therapeutics AI Pharma Product Portfolio
  90. 7.15.5 AI Therapeutics Recent Developments
  91. 7.16 BioMap
  92. 7.16.1 BioMap Company Information
  93. 7.16.2 BioMap Business Overview
  94. 7.16.3 BioMap AI Pharma Revenue and Gross Margin (2021-2026)
  95. 7.16.4 BioMap AI Pharma Product Portfolio
  96. 7.16.5 BioMap Recent Developments
  97. 7.17 METiS Pharmaceuticals
  98. 7.17.1 METiS Pharmaceuticals Company Information
  99. 7.17.2 METiS Pharmaceuticals Business Overview
  100. 7.17.3 METiS Pharmaceuticals AI Pharma Revenue and Gross Margin (2021-2026)
  101. 7.17.4 METiS Pharmaceuticals AI Pharma Product Portfolio
  102. 7.17.5 METiS Pharmaceuticals Recent Developments
  103. 7.18 NeoX Biotech
  104. 7.18.1 NeoX Biotech Company Information
  105. 7.18.2 NeoX Biotech Business Overview
  106. 7.18.3 NeoX Biotech AI Pharma Revenue and Gross Margin (2021-2026)
  107. 7.18.4 NeoX Biotech AI Pharma Product Portfolio
  108. 7.18.5 NeoX Biotech Recent Developments
  109. 7.19 StoneWise
  110. 7.19.1 StoneWise Company Information
  111. 7.19.2 StoneWise Business Overview
  112. 7.19.3 StoneWise AI Pharma Revenue and Gross Margin (2021-2026)
  113. 7.19.4 StoneWise AI Pharma Product Portfolio
  114. 7.19.5 StoneWise Recent Developments
  115. 7.20 Deep Intelligent Pharma
  116. 7.20.1 Deep Intelligent Pharma Company Information
  117. 7.20.2 Deep Intelligent Pharma Business Overview
  118. 7.20.3 Deep Intelligent Pharma AI Pharma Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Deep Intelligent Pharma AI Pharma Product Portfolio
  120. 7.20.5 Deep Intelligent Pharma Recent Developments
  121. 7.21 Gigaceuticals
  122. 7.21.1 Gigaceuticals Company Information
  123. 7.21.2 Gigaceuticals Business Overview
  124. 7.21.3 Gigaceuticals AI Pharma Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Gigaceuticals AI Pharma Product Portfolio
  126. 7.21.5 Gigaceuticals Recent Developments
  127. 7.22 Chemical.AI
  128. 7.22.1 Chemical.AI Company Information
  129. 7.22.2 Chemical.AI Business Overview
  130. 7.22.3 Chemical.AI AI Pharma Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Chemical.AI AI Pharma Product Portfolio
  132. 7.22.5 Chemical.AI Recent Developments
  133. 7.23 Artivila
  134. 7.23.1 Artivila Company Information
  135. 7.23.2 Artivila Business Overview
  136. 7.23.3 Artivila AI Pharma Revenue and Gross Margin (2021-2026)
  137. 7.23.4 Artivila AI Pharma Product Portfolio
  138. 7.23.5 Artivila Recent Developments
  139. 7.24 Galixir
  140. 7.24.1 Galixir Company Information
  141. 7.24.2 Galixir Business Overview
  142. 7.24.3 Galixir AI Pharma Revenue and Gross Margin (2021-2026)
  143. 7.24.4 Galixir AI Pharma Product Portfolio
  144. 7.24.5 Galixir Recent Developments
  145. 7.25 Xbiome
  146. 7.25.1 Xbiome Company Information
  147. 7.25.2 Xbiome Business Overview
  148. 7.25.3 Xbiome AI Pharma Revenue and Gross Margin (2021-2026)
  149. 7.25.4 Xbiome AI Pharma Product Portfolio
  150. 7.25.5 Xbiome Recent Developments
8 North America
  1. 8.1 North America AI Pharma Revenue (2021-2032)
  2. 8.2 North America AI Pharma Revenue by Type (2021-2032)
  3. 8.2.1 North America AI Pharma Revenue by Type (2021-2026)
  4. 8.2.2 North America AI Pharma Revenue by Type (2027-2032)
  5. 8.3 North America AI Pharma Revenue Share by Type (2021-2032)
  6. 8.4 North America AI Pharma Revenue by Application (2021-2032)
  7. 8.4.1 North America AI Pharma Revenue by Application (2021-2026)
  8. 8.4.2 North America AI Pharma Revenue by Application (2027-2032)
  9. 8.5 North America AI Pharma Revenue Share by Application (2021-2032)
  10. 8.6 North America AI Pharma Revenue by Country
  11. 8.6.1 North America AI Pharma Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America AI Pharma Revenue by Country (2021-2026)
  13. 8.6.3 North America AI Pharma Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe AI Pharma Revenue (2021-2032)
  2. 9.2 Europe AI Pharma Revenue by Type (2021-2032)
  3. 9.2.1 Europe AI Pharma Revenue by Type (2021-2026)
  4. 9.2.2 Europe AI Pharma Revenue by Type (2027-2032)
  5. 9.3 Europe AI Pharma Revenue Share by Type (2021-2032)
  6. 9.4 Europe AI Pharma Revenue by Application (2021-2032)
  7. 9.4.1 Europe AI Pharma Revenue by Application (2021-2026)
  8. 9.4.2 Europe AI Pharma Revenue by Application (2027-2032)
  9. 9.5 Europe AI Pharma Revenue Share by Application (2021-2032)
  10. 9.6 Europe AI Pharma Revenue by Country
  11. 9.6.1 Europe AI Pharma Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe AI Pharma Revenue by Country (2021-2026)
  13. 9.6.3 Europe AI Pharma Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China AI Pharma Revenue (2021-2032)
  2. 10.2 China AI Pharma Revenue by Type (2021-2032)
  3. 10.2.1 China AI Pharma Revenue by Type (2021-2026)
  4. 10.2.2 China AI Pharma Revenue by Type (2027-2032)
  5. 10.3 China AI Pharma Revenue Share by Type (2021-2032)
  6. 10.4 China AI Pharma Revenue by Application (2021-2032)
  7. 10.4.1 China AI Pharma Revenue by Application (2021-2026)
  8. 10.4.2 China AI Pharma Revenue by Application (2027-2032)
  9. 10.5 China AI Pharma Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia AI Pharma Revenue (2021-2032)
  2. 11.2 Asia AI Pharma Revenue by Type (2021-2032)
  3. 11.2.1 Asia AI Pharma Revenue by Type (2021-2026)
  4. 11.2.2 Asia AI Pharma Revenue by Type (2027-2032)
  5. 11.3 Asia AI Pharma Revenue Share by Type (2021-2032)
  6. 11.4 Asia AI Pharma Revenue by Application (2021-2032)
  7. 11.4.1 Asia AI Pharma Revenue by Application (2021-2026)
  8. 11.4.2 Asia AI Pharma Revenue by Application (2027-2032)
  9. 11.5 Asia AI Pharma Revenue Share by Application (2021-2032)
  10. 11.6 Asia AI Pharma Revenue by Country
  11. 11.6.1 Asia AI Pharma Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia AI Pharma Revenue by Country (2021-2026)
  13. 11.6.3 Asia AI Pharma Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA AI Pharma Revenue (2021-2032)
  2. 12.2 SAMEA AI Pharma Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA AI Pharma Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA AI Pharma Revenue by Type (2027-2032)
  5. 12.3 SAMEA AI Pharma Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA AI Pharma Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA AI Pharma Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA AI Pharma Revenue by Application (2027-2032)
  9. 12.5 SAMEA AI Pharma Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA AI Pharma Revenue by Country
  11. 12.6.1 SAMEA AI Pharma Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA AI Pharma Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA AI Pharma Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst